

# HPV VACCINES

FOLLOW THE MONEY...


Sales of *Gardasil/Gardasil9* accounted for **\$2.17b** in 2016 - a **14% increase** from 2015 and making up **34.72%** of Merck's total vaccine sales!<sup>1</sup>



*Gardasil/Gardasil9* comprise **5.4%** of global vaccine sales from **all manufacturers**.<sup>2</sup>



GlaxoSmithKline



GlaxoSmithKline's *Cervarix* HPV vaccine made **£81m** in 2016. A **14% reduction** in sales compared with 2015.<sup>3</sup>

99.5% margin

Difference between *Gardasil* cost and sale price.<sup>4</sup>

88% margin

Average cost of manufacture: **\$0.53**  
Sale price: **\$103.49**  
**Developed Countries**


Average cost of manufacture: **\$0.53**  
Sale price: **\$4.50**  
**Gavi\* eligible countries**

\*Gavi ([www.gavi.org/](http://www.gavi.org/)) is an international organisation for equal access to affordable vaccines in developing countries.

Estimated manufacturing cost per *Gardasil* dose to Merck ranges between **\$0.48** and **\$0.59**.<sup>5</sup>



Global Cervical Cancer Incidence<sup>6</sup> versus HPV Vaccine Doses Delivered<sup>7</sup>



**Sub-Saharan Africa** has the **highest cervical cancer incidence**, yet there is an economic and social conflict between **providing food** and **vaccination programs**.

©2017 ALLIANCE FOR NATURAL HEALTH INTERNATIONAL

REFERENCES

- <http://investors.merck.com/news/press-release-details/2017/Merck-Announces-Fourth-Quarter-and-Full-Year-2016-Financial-Results/default.aspx>
- <https://www.statista.com/statistics/265102/revenues-in-the-global-vaccine-market/>
- <https://www.gsk.com/media/3461/q4-2016-results-announcement.pdf>
- <http://apps.who.int/immunization/vaccineprices/en/Navigation/Load?menu=1096&sub=1087>
- <http://onlinelibrary.wiley.com/doi/10.1002/jigo.12186/full>
- <http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp>
- <http://thelancet.com/action/showFullTableImage?tableId=tbl1&pii=S2214109X16300997>

